Smartkarma's AI Co-Pilot, Smartkarma

αSK

Smartkarma's AI Co-Pilot

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/inari-medical-inc">Inari Medical</a> is a leader in the minimally invasive treatment of venous thromboembolism (VTE), with a substantial untapped market opportunity providing a long runway for growth.</li>
 <li>The company is demonstrating robust top-line growth, driven by the adoption of its flagship ClotTriever and FlowTriever products, and is expanding its addressable market through new product launches and international expansion.</li>
 <li>While currently unprofitable on a GAAP basis, management anticipates achieving sustained operating profitability in the first half of 2025, though the company faces increasing competition and risks associated with a DOJ investigation.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Inari Medical is a leader in the minimally invasive treatment of venous thromboembolism (VTE), with a substantial untapped market opportunity providing a long runway for growth.
  The company is demonstrating robust top-line growth, driven by the adoption of its flagship ClotTriever and FlowTriever products, and is expanding its addressable market through new product launches and international expansion.
  While currently unprofitable on a GAAP basis, management anticipates achieving sustained operating profitability in the first half of 2025, though the company faces increasing competition and risks associated with a DOJ investigation.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Inari Medical (NARI US) - Jan 2026

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

VanEck Gold Miners ETF/USA / Technical Analysis

<ul>
<li>The SPX made a high of 4169 last week, tagging our 4165-4200 resistance range. We still believe 4165-4200 will cap upside in 2023, with a reach to 4300-4325 also possible.</li>
<li>Considering limited upside in both scenarios, and with the seasonably weaker "sell in May and go away" period approaching, we continue to recommend higher allocations to defensives</li>
<li>This includes Utilities (XLU, RYU), Consumer Staples (XLP), Health Care (XLV, PPH), and gold miners (GDX).</li>
</ul>


The SPX made a high of 4169 last week, tagging our 4165-4200 resistance range. We still believe 4165-4200 will cap upside in 2023, with a reach to 4300-4325 also possible.
Considering limited upside in both scenarios, and with the seasonably weaker "sell in May and go away" period approaching, we continue to recommend higher allocations to defensives
This includes Utilities (XLU, RYU), Consumer Staples (XLP), Health Care (XLV, PPH), and gold miners (GDX).


"Sell in May" Another Reason to Be Defensive; Value to Lead?; Buys in Medical Devices, Footwear

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Index Rebalance

<ul>
<li>The S&amp;P 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.</li>
<li>In this insight, we take a look at the upcoming constituent changes in the run up to the March 2025 index rebal event.</li>
<li>In this insight, we take a final look at the potential ADDs and DELs leading the rankings for the upcoming review.</li>
</ul>


The S&amp;P 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.
In this insight, we take a look at the upcoming constituent changes in the run up to the March 2025 index rebal event.
In this insight, we take a final look at the potential ADDs and DELs leading the rankings for the upcoming review.


[Quiddity Index Feb25] S&P500/600 Mar25 Rebal: Still the Same Characters

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/axonics-inc" target="_blank" data-smartkarma-citation="entities:36996:1" rel="noopener">Axonics (AXNX US)</a> believes that the U.S. sacral neuromodulation market is now worth of ~$800M, which is poised to double over the next five years to $1.6B.</li>
<li>The company has been reporting superior revenue growth since 2020. Axonics raised 2023 revenue guidance to $358M, up 32% YoY. The company has become adjusted EBITDA positive in 2022.</li>
<li>With superior product portfolio in terms of patient satisfaction, longer product life, and smaller size, Axonics is the stronger player in the U.S. duopoly sacral neuromodulation market.</li>
</ul>



Axonics (AXNX US) believes that the U.S. sacral neuromodulation market is now worth of ~$800M, which is poised to double over the next five years to $1.6B.
The company has been reporting superior revenue growth since 2020. Axonics raised 2023 revenue guidance to $358M, up 32% YoY. The company has become adjusted EBITDA positive in 2022.
With superior product portfolio in terms of patient satisfaction, longer product life, and smaller size, Axonics is the stronger player in the U.S. duopoly sacral neuromodulation market.


Axonics (AXNX US): Large Underserved Market And Superior Portfolio Ensure Multi-Year Growth

Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

Algosun Global

<ul>
<li>We downgrade <a href="https://www.smartkarma.com/entities/inari-medical-inc" target="_blank" data-smartkarma-citation="entities:34650:1" rel="noopener">Inari Medical (NARI US)</a> shares to Neutral and lower a price target to $83.00, implying a ~4% upside. </li>
<li>We see limited upside to <a href="https://www.smartkarma.com/entities/inari-medical-inc" target="_blank" data-smartkarma-citation="entities:34650:1" rel="noopener">Inari Medical (NARI US)</a>  shares due to peer-group multiple compression, slow expansion in Europe and Asia, and rising operating expenses.</li>
<li>
<a href="https://www.smartkarma.com/entities/inari-medical-inc" target="_blank" data-smartkarma-citation="entities:34650:1" rel="noopener">Inari Medical (NARI US)</a> completed SPO, issued 2.3M shares, and raised ~$174M to strengthen the balance sheet in 1Q22.  </li>
</ul>


We downgrade Inari Medical (NARI US) shares to Neutral and lower a price target to $83.00, implying a ~4% upside. 
We see limited upside to Inari Medical (NARI US)  shares due to peer-group multiple compression, slow expansion in Europe and Asia, and rising operating expenses.

Inari Medical (NARI US) completed SPO, issued 2.3M shares, and raised ~$174M to strengthen the balance sheet in 1Q22.  


Inari Medical. Company Update: Downgrade To Neutral

United States

Inari Medical, Inc.manufactures medical device. The Company offers catheter-based technologies for the treatment of venous thromboembolism. Inari Medical serves customers in the State of California.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Inari Medical (NARI US)

Primer: Inari Medical (NARI US) - Jan 2026

Inari Medical is a leader in the minimally invasive treatment of venous thromboembolism (VTE), with a substantial untapped market opportunity...

αSK

"Sell in May" Another Reason to Be Defensive; Value to Lead?; Buys in Medical Devices, Footwear

"Sell in May" Another Reason to Be Defensive; Value Poised to Outperform?; Watching Semiconductors $SOXX $XSD and Banks $KRE $KBE for breakage....

Vermilion Research

[Quiddity Index Feb25] S&P500/600 Mar25 Rebal: Still the Same Characters

The S&P500 is tough to predict (more often than not) because they pick from two pools, and use discretion. The "usual suspects" from last month are...

Travis Lundy

Axonics (AXNX US): Large Underserved Market And Superior Portfolio Ensure Multi-Year Growth

Axonics predicts the U.S. sacral neuromodulation market will double to $1.6B in the next five years. The company is reporting strong revenue...

Tina Banerjee

Inari Medical. Company Update: Downgrade To Neutral

We think the stock is fairly valued at current levels and see limited upside to Inari Medical shares. Our price target supports a Neutral rating.

Andrei Zakharov

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: Inari Medical (NARI US) - Jan 2026

Inari Medical is a leader in the minimally invasive treatment of venous thromboembolism (VTE), with a substantial untapped market opportunity...

αSK

"Sell in May" Another Reason to Be Defensive; Value to Lead?; Buys in Medical Devices, Footwear

"Sell in May" Another Reason to Be Defensive; Value Poised to Outperform?; Watching Semiconductors $SOXX $XSD and Banks $KRE $KBE for breakage....

Vermilion Research

[Quiddity Index Feb25] S&P500/600 Mar25 Rebal: Still the Same Characters

The S&P500 is tough to predict (more often than not) because they pick from two pools, and use discretion. The "usual suspects" from last month are...

Travis Lundy

Axonics (AXNX US): Large Underserved Market And Superior Portfolio Ensure Multi-Year Growth

​Axonics predicts the U.S. sacral neuromodulation market will double to $1.6B in the next five years. The company is reporting strong revenue...

Tina Banerjee

Inari Medical. Company Update: Downgrade To Neutral

We think the stock is fairly valued at current levels and see limited upside to Inari Medical shares. Our price target supports a Neutral rating.

Andrei Zakharov

Axonics predicts the U.S. sacral neuromodulation market will double to $1.6B in the next five years. The company is reporting strong revenue...